Blog
1006 Articles
The Future is Bright
The doctors and researchers at Duke Cancer Institute see a brighter future ahead for pancreatic cancer patients.
Daraxonrasib: What To Know About Common Side Effects
Oncodermatologist Dr. Ian Tattersall discusses the rash caused by the new KRAS drug daraxonrasib, and best options to manage the rash.
Tackling KRAS G12D
Dr. Leon Pappas explains the workings of the new KRAS G12D inhibitor, now in phase I/II clinical trials around the US and Australia.
No Symptoms Whatsoever
In a follow-up visit after her gallbladder was removed, Yariela Martínez’s doctors found stage I pancreatic cancer.
Pancreatic Cancer: The Newest Treatments
Learn more about daraxonrasib and other newest treatments for pancreatic cancer by watching the recording of our webinar.
At the Table: Looking Back at the Last 10 Years
The Let’s Win Patient Advisory Board looks back at changes in the last 10 years for pancreatic cancer treatment, screening, and patient care.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Diet, Exercise, and a Clean Lifestyle
After years of stomach troubles, Mark Olsen found out he had pancreatic cancer. But a genetic mutation made him eligible for immunotherapy.
Learning to Live Again
With a stage IV diagnosis at 33, Matthew Rosenblum thought his life was over. But he’s a long-term survivor and has everything he never thought possible.
Looking Back and Looking Forward
For Let’s Win’s 10th anniversary, long-term survivor Roberta Luna looks back at the changes and forward to future gains.
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Trusting My Gut
Marla Schreffler had a feeling something was wrong, even after she got her diabetes diagnosis. Further tests confirmed that she had pancreatic cancer.
Courageous Conversations—Mastering Patient–Caregiver Communication
Clinical psychologist Stephanie Davidson provides caregivers and patients with techniques to master difficult conversations during treatment.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.